Safety analysis of occupational exposure of healthcare workers to residual contaminations of cytotoxic drugs using FMECA security approach

被引:8
作者
Le, Laetitia Minh Mai [1 ,2 ]
Reitter, Delphine [1 ]
He, Sophie [1 ]
Bonle, Franck Te [1 ]
Launois, Amelie [1 ]
Martinez, Diane [3 ]
Prognon, Patrice [1 ,2 ]
Caudron, Eric [1 ,2 ]
机构
[1] Hop Europeen Georges Pompidou, Dept Pharm, Paris, France
[2] Univ Paris Saclay, Univ Paris Sud, Lip Chim Analyt Pharmaceut Sys2, Chatenay Malabry, France
[3] Hop Europeen Georges Pompidou, Risk Management Dept, Paris, France
关键词
RISK ANALYSIS; FAILURE MODE;
D O I
10.1016/j.scitotenv.2017.05.066
中图分类号
X [环境科学、安全科学];
学科分类号
08 ; 0830 ;
摘要
Handling cytotoxic drugs is associated with chemical contamination of workplace surfaces. The potential mutagenic, teratogenic and oncogenic properties of those drugs create a risk of occupational exposure for healthcare workers, from reception of starting materials to the preparation and administration of cytotoxic therapies. The Security Failure Mode Effects and Criticality Analysis (FMECA) was used as a proactive method to assess the risks involved in the chemotherapy compounding process. FMECA was carried out by a multidisciplinary team from 2011 to 2016. Potential failure modes of the process were identified based on the Risk Priority Number (RPN) that prioritizes corrective actions. Twenty-five potential failure modes were identified. Based on RPN results, the corrective actions plan was revised annually to reduce the risk of exposure and improve practices. Since 2011, 16 specific measures were implemented successively. In six years, a cumulative RPN reduction of 626 was observed, with a decrease from 912 to 286 (-69%) despite an increase of cytotoxic compounding activity of around 23.2%. In order to anticipate and prevent occupational exposure, FMECA is a valuable tool to identify, prioritize and eliminate potential failure modes for operators involved in the cytotoxic drug preparation process before the failures occur. (C) 2017 Elsevier B.V. All rights reserved.
引用
收藏
页码:1939 / 1944
页数:6
相关论文
共 28 条
[1]  
[Anonymous], 2007, CANCSAZ3171001
[2]  
[Anonymous], 2005, D697805 ASTM INT
[3]  
[Anonymous], 2006, Am J Health Syst Pharm
[4]  
Berthe F., 1997, AMDEC SECURITE
[5]   The application of hazard analysis and critical control points and risk management in the preparation of anti-cancer drugs [J].
Bonan, Brigitte ;
Martelli, Nicolas ;
Berhoune, Malik ;
Maestroni, Marie-Laure ;
Havard, Laurent ;
Prognon, Patrice .
INTERNATIONAL JOURNAL FOR QUALITY IN HEALTH CARE, 2009, 21 (01) :44-50
[6]   Use of a prospective risk analysis method to improve the safety of the cancer chemotherapy process [J].
Bonnabry, P ;
Cingria, L ;
Ackermann, M ;
Sadeghipour, F ;
Bigler, L ;
Mach, N .
INTERNATIONAL JOURNAL FOR QUALITY IN HEALTH CARE, 2006, 18 (01) :9-16
[7]  
CDC-Occupational Exposure to Antineoplastic Agents, EFF OCC EXP NIOSH WO
[8]  
CDC-Occupational Exposure to Antineoplastic Agents, ENV SAMPL CONT PROT
[9]  
CDC-Occupational Exposure to Antineoplastic Agents, OCC MON NIOSH WORKPL
[10]   Determination of platinum traces contamination by graphite furnace atomic absorption spectrometry after preconcentration by cloud point extraction [J].
Chappuy, M. ;
Caudron, E. ;
Bellanger, A. ;
Pradeau, D. .
JOURNAL OF HAZARDOUS MATERIALS, 2010, 176 (1-3) :207-212